期刊
MOLECULAR CANCER THERAPEUTICS
卷 10, 期 11, 页码 2062-2071出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-11-0381
关键词
-
类别
资金
- Kentucky Lung Cancer Research Program
- Office of the Executive Vice President for Research at the University of Louisville
- [NIH DK53220]
- [NIH CA138410]
- [NIH F31 EY017275]
- [NIH T35 DK072923]
Mucin 1 (MUC1) is a diagnostic factor and therapy target in lung adenocarcinoma. MUC1 C-terminal intracellular domain (CD) interacts with estrogen receptor (ER) alpha and increases gene transcription in breast cancer cells. Because lung adenocarcinoma cells express functional ER alpha and ER beta, we examined MUC1 expression and MUC1-ER interaction. Because blocking MUC1 CD with an inhibitory peptide (PMIP) inhibited breast tumor growth, we tested whether PMIP would inhibit lung adenocarcinoma cell proliferation. We report that MUC1 interacts with ER alpha and ER beta within the nucleus of H1793 lung adenocarcinoma cells in accordance with MUC1 expression. PMIP was taken up by H23 and H1793 cells and inhibited the proliferation of H1793, but not H23 cells, concordant with higher MUC1 protein expression in H1793 cells. Lower MUC1 protein expression in H23 does not correspond to microRNAs miR-125b and miR-145 that have been reported to reduce MUC1 expression. PMIP had no effect on the viability of normal human bronchial epithelial cells, which lack MUC1 expression. PMIP inhibited estradiol-activated reporter gene transcription and endogenous cyclin D1 and nuclear respiratory factor-1 gene transcription in H1793 cells. These results indicate MUC1-ER functional interaction in lung adenocarcinoma cells and that inhibiting MUC1 inhibits lung adenocarcinoma cell viability. Mol Cancer Ther; 10(11); 2062-71. (C) 2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据